NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

猝睡症:市場洞察,流行病學,市場預測(2027年)

Narcolepsy Market Insight, Epidemiology and Market Forecast - 2030

出版商 DelveInsight Business Research LLP 商品編碼 629175
出版日期 按訂單生產 內容資訊 英文 150 Pages
商品交期: 10個工作天內
價格
猝睡症:市場洞察,流行病學,市場預測(2027年) Narcolepsy Market Insight, Epidemiology and Market Forecast - 2030
出版日期: 按訂單生產內容資訊: 英文 150 Pages
簡介

主要7個國家(美國,英國,德國,法國,義大利,西班牙,日本)的猝睡症的總患病數 2016年達50萬7,138人,同年的市場規模被估計12億6,200萬美元。

本報告提供猝睡症市場相關調查,疾病概要,主要7個國家的市場趨勢,患病數、罹患數及市場規模的變化與預測(過去2年、今後10年份),市場成長要素及障礙分析,已上市/開發中的治療藥的簡介,潛在成長性,目前未滿足需求等總括性彙整。

目錄

第1章 重要洞察

第2章 猝睡症市場概要

  • 市場佔有率(最新值)
  • 市場佔有率(預測值)

第3章 猝睡症:疾病背景和概要

  • 簡介
  • 徵兆與症狀
  • 併發症
  • 病理生理學
  • 病因
  • 危險因素
  • 診斷
  • 治療

第4章 流行病學和患者人口

  • 主要的觀察
  • 人口與預測參數

第5章 主要7個國家猝睡症的總患病數

  • 美國
    • 猝睡症的患病數
    • 猝倒症伴隨/未伴隨的猝睡症的患病數
    • 猝睡症的患病數:各臨床症狀
    • 猝睡症的罹患數
    • 猝睡症的罹患數:各年齡
  • 德國
  • 法國
  • 義大利
  • 西班牙
  • 英國
  • 日本

第6章 目前治療方法與醫療治療

  • 治療次序
  • 指南與管理

第7章 未滿足需求

第8章 已上市的治療藥

  • PROVIGIL
    • 醫藥品概要
    • 法規的里程碑
    • 優點與缺點
    • 產品簡介
  • XYREM

第9章 其他的治療藥物

  • Anafranil(clomipramine)
    • 醫藥品概要
    • 法規的里程碑
    • 優點與缺點
    • 產品簡介
  • Desipramine
  • Prozac(Fluoxetine)
  • Tofranil(Imipramine)
  • Vivactil (Protriptyline)
  • Zoloft (Sertraline)
  • Effexor (Venlafaxine)
  • Desoxyn (Methamphetamine)
  • NUVIGIL
  • Wakix (Pitolisant)
  • Ritalin
  • Dexedrine
  • Adderall
  • Atomoxetine

第10章 開發中的治療藥

  • Xyrem:Jazz Pharmaceuticals
    • 法規的里程碑
    • 臨床開發
    • 臨床試驗資訊
    • 產品的簡介
  • Mazindol CR:NLS Pharma
  • JZP-258:Jazz Pharmaceuticals Inc
  • JZP-110:Jazz Pharmaceuticals Inc
  • Sodium oxybate ER:Avadel Pharmaceuticals
  • TS-091:大正製藥
  • BTD-001:Balance Therapeutics
  • Pitolisant:Bioprojet
  • THN102(Modafinil + Flecainide):Theranexus

第11章 主要7個國家的猝睡症市場分析

第12章 主要7個國家的猝睡症市場預測

第13章 主要7個國家的猝睡症市場:市場規模

第14章 猝睡症市場預測:各國

  • 美國
    • 猝睡症市場:市場規模
    • 猝睡症治療藥市場:市場規模
  • 歐盟5國
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
  • 日本

第15章 市場成長要素

第16章 市場障礙

第17章 附錄

第18章 調查手法

第19章 DelveInsight的服務內容

第20章 免責聲明

第21章 關於DelveInsight

目錄
Product Code: DIMI0005

DelveInsight's "Narcolepsy - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Narcolepsy, historical and forecasted epidemiology as well as the Narcolepsy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Narcolepsy market report provides current treatment practices, emerging drugs, Narcolepsy market share of the individual therapies, current and forecasted Narcolepsy market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Narcolepsy treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Narcolepsy Disease Understanding and Treatment Algorithm

The DelveInsight Narcolepsy market report gives a thorough understanding of the Narcolepsy by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Narcolepsy.

Treatment

It covers the details of conventional and current medical therapies available in the Narcolepsy market for the treatment of the condition. It also provides Narcolepsy treatment algorithms and guidelines in the United States, Europe, and Japan.

Narcolepsy Epidemiology

The Narcolepsy epidemiology division provide insights about historical and current Narcolepsy patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Narcolepsy epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Narcolepsy Epidemiology

The epidemiology segment also provides the Narcolepsy epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Narcolepsy Drug Chapters

Drug chapter segment of the Narcolepsy report encloses the detailed analysis of Narcolepsy marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Narcolepsy clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Narcolepsy treatment.

Narcolepsy Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Narcolepsy treatment.

Narcolepsy Market Outlook

The Narcolepsy market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Narcolepsy market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Narcolepsy market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Narcolepsy market in 7MM is expected to change in the study period 2017-2030.

Key Findings

This section includes a glimpse of the Narcolepsy market in 7MM.

The United States Market Outlook

This section provides the total Narcolepsy market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Narcolepsy market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Narcolepsy market size and market size by therapies in Japan is also mentioned.

Narcolepsy Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Narcolepsy market or expected to get launched in the market during the study period 2017-2030. The analysis covers Narcolepsy market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Narcolepsy Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Narcolepsy key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Narcolepsy emerging therapies.

Reimbursement Scenario in Narcolepsy

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Narcolepsy domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Narcolepsy market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Narcolepsy Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Narcolepsy, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Narcolepsy epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Narcolepsy are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Narcolepsy market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Narcolepsy market

Report Highlights

  • In the coming years, Narcolepsy market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Narcolepsy R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Narcolepsy. Launch of emerging therapies will significantly impact the Narcolepsy market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Narcolepsy
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Narcolepsy Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Narcolepsy Pipeline Analysis
  • Narcolepsy Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Narcolepsy Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage

Narcolepsy Epidemiology Segmentation

  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Narcolepsy Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Narcolepsy market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Narcolepsy total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Narcolepsy market size during the forecast period (2017-2030)?
  • At what CAGR, the Narcolepsy market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Narcolepsy market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Narcolepsy market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the Narcolepsy?
  • What is the historical Narcolepsy patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Narcolepsy in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Narcolepsy?
  • Out of all 7MM countries, which country would have the highest prevalent population of Narcolepsy during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?
  • Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
  • What are the current options for the Narcolepsy treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Narcolepsy in the USA, Europe, and Japan?
  • What are the Narcolepsy marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Narcolepsy?
  • How many therapies are developed by each company for Narcolepsy treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for Narcolepsy treatment?
  • What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Narcolepsy therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Narcolepsy and their status?
  • What are the key designations that have been granted for the emerging therapies for Narcolepsy?
  • What are the global historical and forecasted market of Narcolepsy?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Narcolepsy market
  • To understand the future market competition in the Narcolepsy market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Narcolepsy in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Narcolepsy market
  • To understand the future market competition in the Narcolepsy market

Table of Contents

1. Key Insights

2. Executive Summary of Narcolepsy

3. Competitive Intelligence Analysis for Narcolepsy

4. Narcolepsy: Market Overview at a Glance

  • 4.1. Narcolepsy Total Market Share (%) Distribution in 2017
  • 4.2. Narcolepsy Total Market Share (%) Distribution in 2030

5. Narcolepsy: Disease Background and Overview

  • 5.1. Introduction
  • 5.2. Sign and Symptoms
  • 5.3. Pathophysiology
  • 5.4. Risk Factors
  • 5.5. Diagnosis

6. Patient Journey

7. Narcolepsy Epidemiology and Patient Population

  • 7.1. Epidemiology Key Findings
  • 7.2. Assumptions and Rationale: 7MM
  • 7.3. Epidemiology Scenario: 7MM
    • 7.3.1. Narcolepsy Epidemiology Scenario in the 7MM (2017-2030)
  • 7.4. United States Epidemiology
    • 7.4.1. Narcolepsy Epidemiology Scenario in the United States (2017-2030)
  • 7.5. EU-5 Country-wise Epidemiology
    • 7.5.1. Germany Epidemiology
      • 7.5.1.1. Narcolepsy Epidemiology Scenario in Germany (2017-2030)
    • 7.5.2. France Epidemiology
      • 7.5.2.1. Narcolepsy Epidemiology Scenario in France (2017-2030)
    • 7.5.3. Italy Epidemiology
      • 7.5.3.1. Narcolepsy Epidemiology Scenario in Italy (2017-2030)
    • 7.5.4. Spain Epidemiology
      • 7.5.4.1. Narcolepsy Epidemiology Scenario in Spain (2017-2030)
    • 7.5.5. United Kingdom Epidemiology
      • 7.5.5.1. Narcolepsy Epidemiology Scenario in the United Kingdom (2017-2030)
    • 7.5.6. Japan Epidemiology
      • 7.5.6.1. Narcolepsy Epidemiology Scenario in Japan (2017-2030)

8. Treatment Algorithm, Current Treatment, and Medical Practices

  • 8.1. Narcolepsy Treatment and Management
  • 8.2. Narcolepsy Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Narcolepsy Treatment

11. Marketed Products

  • 11.1. List of Marketed Products in the 7MM
  • 11.2. Drug Name: Company Name
    • 11.2.1. Product Description
    • 11.2.2. Regulatory Milestones
    • 11.2.3. Other Developmental Activities
    • 11.2.4. Pivotal Clinical Trials
    • 11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

  • 12.1. Key Cross
  • 12.2. Drug Name: Company Name
    • 12.2.1. Product Description
    • 12.2.2. Other Developmental Activities
    • 12.2.3. Clinical Development
    • 12.2.4. Safety and Efficacy
    • 12.2.5. Product Profile

List to be continued in report

13. Narcolepsy: Seven Major Market Analysis

  • 13.1. Key Findings
  • 13.2. Narcolepsy Market Size in 7MM
  • 13.3. Narcolepsy Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

  • 15.1. United States: Market Size
    • 15.1.1. Narcolepsy Total Market Size in the United States
    • 15.1.2. Narcolepsy Market Size by Therapies in the United States
  • 15.2. EU-5 countries: Market Size and Outlook
  • 15.3. Germany Market Size
    • 15.3.1. Narcolepsy Total Market Size in Germany
    • 15.3.2. Narcolepsy Market Size by Therapies in Germany
  • 15.4. France Market Size
    • 15.4.1. Narcolepsy Total Market Size in France
    • 15.4.2. Narcolepsy Market Size by Therapies in France
  • 15.5. Italy Market Size
    • 15.5.1. Narcolepsy Total Market Size in Italy
    • 15.5.2. Narcolepsy Market Size by Therapies in Italy
  • 15.6. Spain Market Size
    • 15.6.1. Narcolepsy Total Market Size in Spain
    • 15.6.2. Narcolepsy Market Size by Therapies in Spain
  • 15.7. United Kingdom Market Size
    • 15.7.1. Narcolepsy Total Market Size in the United Kingdom
    • 15.7.2. Narcolepsy Market Size by Therapies in the United Kingdom
  • 15.8. Japan Market Outlook
    • 15.8.1. Japan Market Size
    • 15.8.2. Narcolepsy Total Market Size in Japan
    • 15.8.3. Narcolepsy Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Narcolepsy

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

  • 20.1. Bibliography
  • 20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

List of Tables

  • Table 1 : 7MM Narcolepsy Epidemiology (2017-2030)
  • Table 2 : 7MM Narcolepsy Diagnosed and Treatable Cases (2017-2030)
  • Table 3 : Disease% Epidemiology in the United States (2017-2030)
  • Table 4 : Narcolepsy Diagnosed and Treatable Cases in the United States (2017-2030)
  • Table 5 : Narcolepsy Epidemiology in Germany (2017-2030)
  • Table 6 : Narcolepsy Diagnosed and Treatable Cases in Germany (2017-2030)
  • Table 7 : Narcolepsy Epidemiology in France (2017-2030)
  • Table 8 : Narcolepsy Diagnosed and Treatable Cases in France (2017-2030)
  • Table 9 : Narcolepsy Epidemiology in Italy (2017-2030)
  • Table 10 : Narcolepsy Diagnosed and Treatable Cases in Italy (2017-2030)
  • Table 11 : Narcolepsy Epidemiology in Spain (2017-2030)
  • Table 12 : Narcolepsy Diagnosed and Treatable Cases in Spain (2017-2030)
  • Table 13 : Narcolepsy Epidemiology in the UK (2017-2030)
  • Table 14 : Narcolepsy Diagnosed and Treatable Cases in the UK (2017-2030)
  • Table 15 : Narcolepsy Epidemiology in Japan (2017-2030)
  • Table 16 : Narcolepsy Diagnosed and Treatable Cases in Japan (2017-2030)
  • Table 17 : Drug Name, Clinical Trials by Recruitment status
  • Table 18 : Drug Name, Clinical Trials by Zone
  • Table 19 : Total Seven Major Market Size in USD, Million (2017-2030)
  • Table 20 : Region-wise Market Size in USD, Million (2017-2030)
  • Table 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Table 22 : United States Market Size in USD, Million (2017-2030)
  • Table 23 : United States Market Size by Therapy in USD, Million (2017-2030)
  • Table 24 : Germany Market Size in USD, Million (2017-2030)
  • Table 25 : Germany Market Size by Therapy in USD, Million (2017-2030)
  • Table 26 : France Market Size in USD, Million (2017-2030)
  • Table 27 : France Market Size by Therapy in USD, Million (2017-2030)
  • Table 28 : Italy Market Size in USD, Million (2017-2030)
  • Table 29 : Italy Market Size by Therapy in USD, Million (2017-2030)
  • Table 30 : Spain Market Size in USD, Million (2017-2030)
  • Table 31 : Spain Market Size by Therapy in USD, Million (2017-2030)
  • Table 32 : United Kingdom Market Size in USD, Million (2017-2030)
  • Table 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Table 34 : Japan Market Size in USD, Million (2017-2030)
  • Table 35 : Japan Market Size by Therapy in USD, Million (2017-2030)

List of Figures

  • Figure 1 : 7MM Narcolepsy Epidemiology (2017-2030)
  • Figure 2 : 7MM Narcolepsy Diagnosed and Treatable Cases (2017-2030)
  • Figure 3 : Narcolepsy Epidemiology in the United States (2017-2030)
  • Figure 4 : Narcolepsy Diagnosed and Treatable Cases in the United States (2017-2030)
  • Figure 5 : Narcolepsy Epidemiology in Germany (2017-2030)
  • Figure 6 : Narcolepsy Diagnosed and Treatable Cases in Germany (2017-2030)
  • Figure 7 : Narcolepsy Epidemiology in France (2017-2030)
  • Figure 8 : Narcolepsy Diagnosed and Treatable Cases in France (2017-2030)
  • Figure 9 : Narcolepsy Epidemiology in Italy (2017-2030)
  • Figure 10 : Narcolepsy Diagnosed and Treatable Cases in Italy (2017-2030)
  • Figure 11 : Narcolepsy Epidemiology in Spain (2017-2030)
  • Figure 12 : Narcolepsy Diagnosed and Treatable Cases in Spain (2017-2030)
  • Figure 13 : Narcolepsy Epidemiology in the UK (2017-2030)
  • Figure 14 : Narcolepsy Diagnosed and Treatable Cases in the UK (2017-2030)
  • Figure 15 : Narcolepsy Epidemiology in Japan (2017-2030)
  • Figure 16 : Narcolepsy Diagnosed and Treatable Cases in Japan (2017-2030)
  • Figure 17 : Drug Name, Clinical Trials by Recruitment status
  • Figure 18 : Drug Name, Clinical Trials by Zone
  • Figure 19 : Total Seven Major Market Size in USD, Million (2017-2030)
  • Figure 20 : Region-wise Market Size in USD, Million (2017-2030)
  • Figure 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Figure 22 : United States Market Size in USD, Million (2017-2030)
  • Figure 23 : United States Market Size by Therapy in USD, Million (2017-2030)
  • Figure 24 : Germany Market Size in USD, Million (2017-2030)
  • Figure 25 : Germany Market Size by Therapy in USD, Million (2017-2030)
  • Figure 26 : France Market Size in USD, Million (2017-2030)
  • Figure 27 : France Market Size by Therapy in USD, Million (2017-2030)
  • Figure 28 : Italy Market Size in USD, Million (2017-2030)
  • Figure 29 : Italy Market Size by Therapy in USD, Million (2017-2030)
  • Figure 30 : Spain Market Size in USD, Million (2017-2030)
  • Figure 31 : Spain Market Size by Therapy in USD, Million (2017-2030)
  • Figure 32 : United Kingdom Market Size in USD, Million (2017-2030)
  • Figure 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Figure 34 : Japan Market Size in USD, Million (2017-2030)
  • Figure 35 : Japan Market Size by Therapy in USD, Million (2017-2030)